The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-sev ...

Takeda is rolling out its first rare disease CTV campaign for its chronic inflammatory demyelinating polyneuropathy (CIDP) ...

The Food and Drug Administration (FDA) has approved Steqeyma ® (ustekinumab-stba), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases in adults and ...

Viridian's veligrotug shows promising results in treating TED patients, setting the stage for future growth in the ...

Sarcopenia and Muscle Loss After age 30, muscle loss begins, and by 40, the effects accelerate. This process, known as ...

A study found that people who engaged in consistent physical activity had a greater ability to store fat subcutaneously ...

Biohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and regulatory milestones.

The FDA cited issues with a manufacturing facility as the reason for the rejection. J&J is currently “working closely” with ...

Valentino Stella served as a consultant in developing Vyalev, which is delivered subcutaneously to Parkinson’s patients through a wearable pump that’s smaller, more comfortable and effective at ...

As the most upstream component of the renin-angiotensin-aldosterone system, angiotensinogen represents an attractive target ...

The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately ...

Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...